New Risk • May 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m (CA$180k revenue, or US$130k). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€15.4m market cap, or US$18.0m). Announcement • May 23
Ventripoint Diagnostics Ltd. announced that it has received CAD 0.30803 million in funding Ventripoint Diagnostics Ltd. announced the closing of a non-brokered private placement of 2,800,273 units at a price of CAD 0.11 per Unit for aggregate gross proceeds of CAD 308,030.03 on May 22, 2026. Each Unit will be comprised of one common share of the Corporation, and one common share purchase warrant. Each whole Warrant will entitle the holder thereof to purchase one Common Share at a price of CAD 0.14 for a period of 24 months from the closing of the Offering. The transaction is subject to TSXV Venture Exchange (the “Exchange”) acceptance. No finders’ fees were paid related to the Offering. An insider of the Corporation subscribed for 136,364 Units for proceeds of CAD 15,000.04. All securities issued and issuable pursuant to the Offering will be subject to a hold period of four months plus one day from the date of closing of the Offering. The Offering is subject to approval by the Exchange. Announcement • Apr 24
Ventripoint Diagnostics Ltd. has filed a Follow-on Equity Offering. Ventripoint Diagnostics Ltd. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 555,699 Announcement • Mar 17
Ventripoint Diagnostics Ltd., Annual General Meeting, May 27, 2026 Ventripoint Diagnostics Ltd., Annual General Meeting, May 27, 2026. Location: ontario, toronto Canada Announcement • Jan 19
Ventripoint Diagnostics Ltd. announced that it has received CAD 1.009772 million in funding On January 19, 2026, Ventripoint Diagnostics Ltd. closed the transaction. The company issued 10,097,720 units at a price of CAD 0.10 per unit for gross proceeds of CAD 1,009,772. Directors and Officers of the company (insiders) invested an aggregate of CAD 139,340, which was 13.8% of the total proceeds. The corporation has paid cash finder’s fees of CAD 15,600 and issued common share purchase warrants (“finder’s warrants”) to purchase an aggregate of 156,000 shares of the company. Each finder’s warrant will be exercisable into one common share at an exercise price of CAD 0.13 per common share for a period of 24 months from the closing of the offering. Announcement • Jan 01
Ventripoint Diagnostics Ltd. announced that it expects to receive CAD 0.5 million in funding Ventripoint Diagnostics Ltd. announced a non-brokered private placement of up to 5,000,000 units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 500,000 on December 31, 2025. Each unit will comprise one common share of the corporation and one common share purchase warrant. Each whole warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.13 for a period of 24 months from the closing of the offering. The corporation may pay cash finder's fee and issue common share purchase warrants of up to CAD 0.08 of the gross proceeds of the offering. Each finder's warrant will be exercisable into one common share at an exercise price of CAD 0.13 per common share for a period of 24 months from the closing of the offering. All securities issued and issuable pursuant to the offering will be subject to a hold period of four months plus one day from the date of closing of the offering. The offering is subject to approval by the exchange. Announcement • Dec 12
Ventripoint Diagnostics Ltd. Unveils Global Model for A.I.- Enhanced Heart Care Through Partnership with the Nisga'a Valley Health Authority Ventripoint Diagnostics Ltd. announced a transformative partnership with Nisga'a Valley Health Authority (NVHA) that is the next step towards forming a new model for delivering accessible, high-quality heart care powered by artificial intelligence. The new model follows a "hub-and-spoke" design, where a central hub with advanced cardiac capabilities provides support to connected sites in smaller, remote, and Indigenous communities. Local healthcare providers can acquire, enhance and read ultrasound scans using VMS+™? and transmit them digitally as needed to specialists at the hub for rapid interpretation and consultation. The Nisga'a Valley health Authority will serve as the first remote site in this expanding network, and will be linked to a regional centre with tertiary and quaternary care capabilities. Future phases are intended to include: Additional First Nations communities in British Columbia and all of Canada. Arctic regions across the country. Rural and northern communities worldwide. Communities in the Amazon, Africa, India, and other regions where MRI access is limited. This expected results of the model are simple yet profound: delivering advanced cardiac imaging directly to patients - Indigenous and non-Ind Indigenous - without the need for long-distance travel, high costs, or extended wait times. At the core of this model is Ventripoint's VMS+™? system, which delivers MRI-level heart measurement accuracy by transforming standard 2D echocardiograms into 3D volumetric images. This technology enables precise cardiac assessments to be performed at the point of care, reducing costs and eliminating the need for time-consuming MRI scans. The system is already being used to support diagnosis and monitoring of indications such as congenital heart disease, post-surgical recovery, chemotherapy-related cardiac complications, pulmonary hypertension, heart failure, and valve dysfunction. Ventripoint plans to expand this model throughout Canada and internationally, advancing the goal of universal access to affordable, accurate cardiac diagnostics. Announcement • Dec 04
Ventripoint Diagnostics Ltd. Announces Chief Financial Officer Changes Ventripoint Diagnostics Ltd. announced the appointment of David Swetlow, CPA, CA, iGP as Chief Financial Officer (CFO), effective immediately. This appointment represents an important step in strengthening Ventripoints leadership team as the Company embarks on its new commercial strategic vision and transitions into its growth phase. Mr. Swetlow brings extensive senior management, financial and public company leadership experience from various roles across high-growth medical technology and innovative life science companies, including Sernova, Ondine, Protox, HealthPricer, One Person Health, QLT and Xillix, with a track record of building and executing robust capital markets strategies; company scale up, product launch and commercialization strategies success; driving and evolving financial systems, reporting, and operational performance for next stage growth; strategic relationship management; and enhancing corporate governance. His broad expertise will be instrumental to positioning VPT to achieve the next stage of VMS+ platform market adoption success and expansion abroad. This is a pivotal moment for Ventripoint, said Hugh MacNaught, President &CEO of Ventripoint Diagnostics. Davids leadership will play a vital role as we execute on a refreshed commercial strategy designed to scale our technology and platform, strengthen our global partnerships, and position the company for new markets and revenue growth. As Ventripoint moves into this next stage, the Company also extends its appreciation to Jimmy Jeon, who has resigned as CFO and Marelli Services for their valuable support to date. Their contributions have helped provide stability and continuity through a period of important transition. As CFO, Mr. Swetlow will oversee financial strategy, capital markets, financial reporting and operations, working closely with the executive team and Board of Directors as VPT advances commercialization efforts in the U.S., Canada, Europe, the UK, and other priority markets. Announcement • Aug 26
Ventripoint Diagnostics Ltd. announced that it expects to receive CAD 0.5 million in funding Ventripoint Diagnostics Ltd. a non-brokered private placement to issue unsecured convertible debenture units for gross proceeds of CAD 500,000 on August 26, 2025. Each Unit will be comprised of one unsecured convertible debenture principal amount of CAD 1,000 convertible into common shares of the Corporation, and 9,000 common share purchase warrants Depending on market conditions, the Corporation may increase the size of the Offering, subject to approval of the Exchange. The Debentures will be convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity at a conversion price of CAD 0.11 per Common Share. The Debentures will mature December 31, 2027 and will bear interest at 10% payable semi-annually in arrears in either cash or at the option of the Corporation by issuance of Common Shares at a 20-day VWAP market price, determined at time of payment, subject to Exchange approval. Announcement • Apr 29
Ventripoint Diagnostics Ltd., Annual General Meeting, Jul 02, 2025 Ventripoint Diagnostics Ltd., Annual General Meeting, Jul 02, 2025. Location: ontario, toronto Canada Announcement • Mar 23
Ventripoint Diagnostics Ltd. announced that it has received CAD 0.5 million in funding On March 21, 2025, Ventripoint Diagnostics Ltd. closed the transaction. The company issued 500 unsecured convertible debenture units at a price of CAD 1,000 per unit for gross proceeds of CAD 500,000 in the transaction. Each whole warrant will entitle the holder thereof to purchase one common share until June 28, 2027. The corporation paid aggregate cash finder’s fees of CAD 4,320 and issued an aggregate of 30,857 common share purchase warrants to finders in connection with the offering. Announcement • Mar 14
Ventripoint Diagnostics Ltd. announced that it expects to receive CAD 0.5 million in funding Ventripoint Diagnostics Ltd. announces a non-brokered private placement of unsecured convertible debenture units for gross proceeds of CAD 500,000 on March 14, 2025. Each Unit will be comprised of 1 unsecured convertible debenture convertible into common shares and 7,143 common share purchase warrants. The Debentures will be convertible into Common Shares of the Company at the option of the holder at any time prior to maturity at a conversion price of $0.14 per Common Share. Each whole Warrant will entitle the holder thereof to purchase 1 Common Share at a price of CAD 0.18. The Debentures will mature June 28, 2027 and will bear interest at 10%. All securities issued and issuable pursuant to the Offering will be subject to a hold period of four months plus one day from the date of closing of the Offering. The Offering is subject to approval by the Exchange. Announcement • Jan 22
Ventripoint Diagnostics Ltd. Updates Submission to U.S. Food and Drug Administration for Its Next Generation, AI-Powered Heart Scanning Technology Ventripoint Diagnostics Ltd. has reached another development milestone by updating the submission of its next generation of software, VMS+ 4.0, to the U.S. Food and Drug Administration ("FDA") for clearance. The update addresses questions regarding cybersecurity and AI. This latest advancement of Ventripoint's proprietary technology, VMS+ 4.0, delivers two significant enhancements to improve clinical workflows: AI-assisted echocardiogram image analysis; and Simplified sensors pairing workflow. These new improvements are in addition to the benefits of VMS+ 3.0: Full-scope use so all patient groups can be easily scanned and assessed; Magnet-free sensors increasing the scope of patients who can benefit; and Vendor-neutral interfacing with any ultrasound machine. Ventripoint updated its submission of VMS+ 4.0 for clearance by the FDA on January 17, 2025 to meet a requirement for significant software and hardware updates and diagnostic advances. VMS+ 4.0 has already secured regulatory clearance in other key markets such as the E.U., U.K. and Canada making this latest version of VMS+ available to the global community. Earlier versions of Ventripoint's scanning technology received FDA, Health Canada and E.U. regulatory approvals and are being used by leading hospitals in the U.S., E.U., U.K. and Canada. Announcement • Nov 16
Ventripoint Diagnostics Ltd. announced that it has received CAD 1.554925 million in funding On November 14, 2024, Ventripoint Diagnostics Ltd. closed the transaction. The company issued 494,041 units of the company at a price of CAD 0.195 per unit for gross proceeds of CAD 96,338 in its final tranche. In total, the company issued an aggregate of 2,845,771 units pursuant to the LIFE offering for aggregate gross proceeds of CAD 554,925. New Risk • Oct 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CA$2.1m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (CA$72k revenue, or US$52k). Minor Risks Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Market cap is less than US$100m (€16.1m market cap, or US$17.4m). Announcement • Oct 25
Ventripoint Diagnostics Ltd. Receives EU CE Mark for Next Generation, AI-Powered Heart-Scanning Technology Ventripoint Diagnostics Ltd. announced CE Mark certification for its latest offering, VMS+4.0. This marks a significant milestone for Ventripoint as it continues to innovate and provide cutting-edge solutions to healthcare professionals worldwide. The certification will allow Ventripoint to engage in the next steps of country-specific entrance of VMS+4.0 in the European Union (EU) and other geographies that recognize CE marking. VMS+4.0 offers a significant improvement in user experience through the automation of the image processing steps. This streamlined workflow leads to a significant reduction in operator time without compromising the accuracy of the measurements. Additionally, this release is optimized to work seamlessly with Ventripoint's magnet-free sensors, further enhancing efficiency and ease of use. VMS+V4.0 will be marketed as a premium product in Europe to complement base product V3.2. VMS+ 4.0 has already a Medical Device License in Canada, and is under review by US-FDA. VMS+ V3.2 is being used by leading hospitals in the U.S., E.U., U.K. and Canada. Announcement • Oct 11
Ventripoint Diagnostics Ltd. Submits its Next Generation of Software and Hardware, VMS+4.0 Ventripoint Diagnostics Ltd. announced that it has submitted its next generation of software and hardware, VMS+4.0, for approval under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Company has received notification its submission is complete and is now under active review by the notified body and expects approval in November This marks a significant step forward in the regulatory approval process for this new version of VMS+, which reduces the need for manual inputs and more easily integrates with clinical workflow through further AI-powered automation. Ventripoint's VMS+ uses AI to transform ultrasound scans, taken in minutes, into high-quality images of all four chambers of the heart that is a faster and cheaper alternative to MRIs. The technology is now in use in hospitals in the U.S., Europe, the UK and Canada. The VMS+4.0 has received a Medical Device License from Health Canada and is being offered to leading hospitals within Canada. Ventripoint submitted VMS+4.0 for clearance by US-FDA and has received a first office response, which requested additional information. The Company is actively addressing these questions and expects to submit a detailed package by the end of the year. EU MDR is the European Union Medical Device Regulation 2017/745 that was adopted in 2017 by the European Parliament and the Council of the European Union. The intent of the EU MDR is to ensure a high standard of safety and quality for medical devices that are produced in, or supplied to, member countries of the European Union. This latest advance of Ventripoint's AI-powered technology, which rapidly processes ultrasound images of the heart to generate MRI-quality measurements of all four cardiac chambers has incorporated features requested by users to all a more seamless integration into the workflow of hospitals, clinics and caregivers. The advances achieved by VMS+4.0 include: Novel presentation of all four 3D reconstructed chambers of the heart through the cardiac cycle - the beating heart; Automated plotting of key anatomical landmarks of the heart, reducing the need for manual inputs. This provides the higher reliability, consistency and reproducibility of the volumetric measurements and most importantly - a greater confidence in the analysis; Increased analysis speed, making heart analysis available in minutes on the first visit, and not the hours needed for MRI imaging; Full-scope use -- meaning newborns to adults can be easily scanned and assessed; Magnet-free sensors, which reduces procedure time by eliminating a calibration step; Enhanced visualization tools. Reported Earnings • Sep 01
Second quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2023) Second quarter 2024 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2023). Revenue: CA$30.7k (up CA$26.8k from 2Q 2023). Net loss: CA$1.42m (loss widened 27% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Announcement • Aug 29
Ventripoint Diagnostics Ltd. announced that it expects to receive CAD 3.5 million in funding Ventripoint Diagnostics Ltd. announced a non-brokered private placement to issue 2,564,103 units at a issue price of CAD 0.195 per unit for gross proceeds of CAD 500,000 and 3,000 unsecured convertible debentures at a issue price of CAD 1,000 per debenture for gross proceeds of CAD 3,000,000 for aggregate gross proceeds of CAD 3,500,000 on August 28, 2024. Each Unit will consist of one common share of the Corporation and one Share purchase warrant of the Corporation. Each Warrant will entitle the holder to purchase one Share at a price of CAD 0.30 per Warrant Share at any time on or before the date which is 6 months after the issuance of the Warrant, subject to adjustment in certain events. The Corporation may pay cash finder’s fees of up to 4% of the gross proceeds of the LIFE Offering. Finders may also receive common share purchase warrants equal to up to 4% of the aggregate subscription amount in relation to subscribers introduced by the finder, each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CAD 0.195 per Common Share for a period of 6 months. The debentures will mature on June 28, 2027 from date of issuance. The Debentures will bear simple interest at an annual rate of 10%. The principal amount of each Debenture will be convertible, at the option of the holder, into common shares of the Corporation for an effective exercise price of CAD 0.195 per Common Share or the first year and CAD 0.25 thereafter. The Corporation may pay a cash finder’s fee of up to 4% of the gross proceeds of the CD Offering. Finders may also receive common share purchase warrants equal to up to 4% of the aggregate subscription amount in relation to subscribers introduced by the finder, each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CAD 0.195 per Common Share for a period of 18 months. All securities issued and issuable pursuant to the CD Offering will be subject to a hold period of four months plus one day from the date of closing of the CD Offering. The CD Offering is subject to approval by the TSXV. Announcement • Aug 21
Ventripoint Diagnostics Ltd. Receives Medical Device License from Health Canada Ventripoint Diagnostics Ltd. announced that it has received a Medical Device License from Health Canada for its latest product offering, VMS+4.0. This is a major milestone for Ventripoint as it continues to innovate and provide cutting-edge solutions to cardiac clinicians worldwide. VMS+4.0 offers a significant improvement in user experience through the automation of the image processing steps. This streamlined workflow leads to a significant reduction in operator time without compromising the accuracy of the measurements. Additionally, this release is optimized to work seamlessly with Ventripoint's recently announced magnet-free sensors, further enhancing efficiency, ease of use and applicability. Reported Earnings • Jun 04
First quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2023) First quarter 2024 results: CA$0.008 loss per share (improved from CA$0.009 loss in 1Q 2023). Net loss: CA$1.19m (loss narrowed 12% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 01
Full year 2023 earnings released: CA$0.031 loss per share (vs CA$0.031 loss in FY 2022) Full year 2023 results: CA$0.031 loss per share (in line with FY 2022). Net loss: CA$4.87m (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Announcement • Apr 11
VentriPoint Diagnostics Ltd. announced that it expects to receive CAD 3 million in funding Ventripoint Diagnostics Ltd announced a non-brokered private placement of 3,000 unsecured convertible debentures for an issue price of CAD 1,000 per debenture for a gross proceeds of CAD 3,000,000 on April 11, 2024. The debentures bear 10% interest and mature 3 years from date of issuance. The principal amount of each Debenture will be convertible, at the option of the holder, into 4,000 common shares of the corporation for an effective exercise price of CAD 0.25 per Common Share. The Debentures will bear simple interest at an annual rate of 10%, calculated on the principal amount, with any accrued but unpaid interest under the Debentures due and payable semi-annually in arrears in either cash or at the option of the Corporation 40% cash and 60% Common Shares, with the number of Common Shares being determined by using the 20-day volume-weighted average price of the Common Shares on the Exchange on that date that is five days prior to the last trading day of the applicable period. The Debentures will convert automatically into Common Shares of the Corporation in the event the Corporations’ Common Shares closing price prior to October 20, 2026 exceeds 100% of the Conversion Price on the Exchange for 5 consecutive trading days based on volume weighted average closing price. In the event of Automatic Conversion, each Debenture holder will receive warrants to purchase that number of Common Shares as is equal to 50% of the shares issuable on conversion of the Debentures until October 20, 2026, at an exercise price of CAD 0.70 per share. The Corporation may pay cash finder’s fee of up to 4% of the gross proceeds of the Offering. Finders may also receive common share purchase warrants equal to up to 4% of the aggregate subscription amount in relation to subscribers introduced by the finder, each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CAD 0.25 per Common Share for a period of 18 months. All securities issued and issuable pursuant to the Offering will be subject to a hold period of four months plus one day from the date of closing of the Offering. The Offering is subject to approval by the Exchange. Announcement • Jan 22
VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board VentriPoint Diagnostics Ltd. announced the appointment of Dr. Luc Mertens one of Canada's and the world's top practitioners of echocardiography to Clinical Advisory Board. Dr. Mertens, MD, PhD, is the current Section Head of Echocardiography at the Hospital for Sick Children in Toronto, Canada, and is also a Professor at the University of Toronto. His achievements and expertise are globally recognized in the echocardiography community. Dr. Mertens received his medical degree from the University of Leuven in Belgium and trained as a Pediatric Cardiologist at the University of Leuven and at The Mayo Clinic in Rochester, MN (USA). He worked as a paediatric cardiologist at the University Hospitals in Leuven between 1998 and 2008, focusing on paediatric echocardiography and studying cardiac function in children. Dr. Mertens has also received international recognition as the Feigenbaum Lecturer for the American Society of Echocardiography Scientific Sessions in 2014, as well as the Founding Chair of the European Accreditation Committee for Pediatric and Congenital Echocardiography in 2004. Announcement • Nov 25
VentriPoint Diagnostics Ltd. to Report Q3, 2023 Results on Nov 29, 2023 VentriPoint Diagnostics Ltd. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 29, 2023 Announcement • Oct 05
VentriPoint Diagnostics Ltd. Announces Executive Changes VentriPoint Diagnostics Ltd. announced the appointment of Mr. Jimmy Jeon as Chief Financial Officer (CFO) of the Company. Mr. Jeon replaces Mr. Victor Hugo, who has served as CFO since June 2020. Mr. Jeon currently works as a Senior Financial Analysist at Marrelli Support Services Inc. where he provides CFO, accounting, regulatory compliance, and management advisory services to numerous public trading companies on the TSX, TSX Venture Exchange and other Canadian and U.S. exchanges. Mr. Jeon is a CPA and holds a Bachelor of Business Administration and Graduate Diploma in Accounting from Wilfrid Laurier University. Mr. Jeon has over 6 years experience in various sectors, with responsibility for accounting, budgeting, financial reporting and disclosures. Announcement • Aug 26
VentriPoint Diagnostics Ltd. to Report Q2, 2023 Results on Aug 29, 2023 VentriPoint Diagnostics Ltd. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 29, 2023 Announcement • Aug 19
Ventripoint Diagnostics Ltd. Announces That Ventripoint and Ascend Cardiovascular, Llc Have Developed A New Integrated Product VentriPoint Diagnostics Ltd. announced that Ventripoint and ASCEND Cardiovascular, LLC have developed a new integrated product. ASCEND fits perfectly into Ventripoint's roadmap for innovation and is a key step in the company's mission to improve patient's lives and become the standard of care. ASCEND is seamlessly integrated with leading EHRs, and imaging systems. Their existing technology has been installed at 1000+ top ranked healthcare facilities and 600+ health systems with approximately 50,000 users across the United States. Ventripoint has successfully and seamlessly integrated its specialized AI-powered 3D Echo software application with ASCEND's diagnostic viewer, InView, and reporting application, Cardiovascular Structured Reporting. This cardiovascular workflow product provides an end-to-end solution that rivals other products on the market. It is streamlined, smart, and effective for cardiology reading, reporting, and diagnostics, thereby improving diagnosis and monitoring of fetal, pediatric, and adult congenital heart disease. As the collaboration between Ventripoint and ASCEND continues to evolve, both companies remain committed to driving innovation and excellence in cardiovascular health technology. Announcement • May 30
VentriPoint Diagnostics Ltd. to Report Q1, 2023 Results on May 30, 2023 VentriPoint Diagnostics Ltd. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 30, 2023 Board Change • Jan 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 5 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Executive Chairman George Adams is the most experienced director on the board, commencing their role in 2010. Independent Director Hugh MacNaught was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Executive Chairman & Interim CEO George Adams is the most experienced director on the board, commencing their role in 2010. Independent Director Hugh MacNaught was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jan 06
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 4 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Executive Chairman & Interim CEO George Adams is the most experienced director on the board, commencing their role in 2010. Independent Director Hugh MacNaught was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Board Change • Nov 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Richard Krasuski is the most experienced director on the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • May 04
Full year 2020 earnings released: CA$0.025 loss per share (vs CA$0.052 loss in FY 2019) Full year 2020 results: Net loss: CA$1.85m (loss narrowed 44% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 12
New 90-day high: €0.23 The company is up 357% from its price of €0.05 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 23% over the same period. Is New 90 Day High Low • Feb 10
New 90-day high: €0.22 The company is up 348% from its price of €0.05 on 11 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 24% over the same period. Recent Insider Transactions • Jan 22
Independent Director recently sold €56k worth of stock On the 19th of January, Robert Hodgkinson sold around 500k shares on-market at roughly €0.11 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €198k more than they bought in the last 12 months. Recent Insider Transactions • Oct 20
Executive Chairman & CEO recently sold €136k worth of stock On the 13th of October, George Adams sold around 2m shares on-market at roughly €0.078 per share. This was the largest sale by an insider in the last 3 months. This was George's only on-market trade for the last 12 months. 
